Effects of COVID-19 Lockdown on Diabetic Macular Edema Treatment

Serdar Bilici; Neriman Selçuk; Tuba Gültekin-erol; Suat Hayri Uğurbaş

Article Details

Effects of COVID-19 Lockdown on Diabetic Macular Edema Treatment

Authors:

Serdar Bilici | Neriman Selçuk | Tuba Gültekin-erol | Suat Hayri Uğurbaş

Publisher:

Zonguldak Bulent Ecevit University

Main Topics:

Sağlık Kurumları Yönetimi

Journal:

Türkiye Diyabet ve Obezite Dergisi Vol.7 Issue 2, pp.122-127

Document Type:

Article

Publication Date:

8/2023

Document Language:

Turkish

Document ID (Org No.):

2001297818

pISSN:

2587-0335

Keywords:

Abstract:

 Aim: Evaluating the anatomical and functional effects of delay in diabetic macular edema treatment due to the COVID-19 lockdown. Material and Methods: DME cases of which anti-vascular growth factor VEGF treatment was interrupted due to COVID-19 lockdown were included in the study. Age, gender, interval time of the treatment delay, number of injections after retreatment and follow-up period were recorded. Visual acuity VA and central macular thickness CMT of the participants at the last visit before the lockdown V0, the first V1 and the last V2 visit after the lockdown were evaluated. The cases were divided into subgroups based on delay in treatment: 18 weeks or less Group-1 and over 18 weeks Group-2. Results: 89 eyes of 89 patients with average age of 63.1 42-80 were included in the study. The average delay in the treatment during the pandemic period was 21.03 12-48 weeks. The average follow-up period after the initiation of retreatment was 31.2 8-52 weeks, and an average of 2.98 1-8 anti-VEGF treatments were carried out during this period. The mean VA of V0, V1 and V2 visits of the whole group were determined as 0.64, 0.64, and 0.63 LogMAR p0.168, respectively, the mean CMT values were found as 383.06, 434.82, and 373.27 microns p0.001, respectively. The mean VA of V0, V1 and V2 visits were 0.53, 0.50 and 0.52 LogMAR p0.263 in Group 1 and, 0.78, 0.83 and 0.74 LogMAR p0.176 in Group 2, respectively. The mean CMT values of V0, V1 and V2 visits were found as 358.72, 386.59 and 389.70 microns p0.056 in Group 1 and, 409.09, 486.42 and 355.70 p0.001 in Group 2, respectively. Conclusion: In DME cases, as the delay time in anti-VEGF treatment increased, worsening was observed in CMT, while CMT values improved without any worsening in VA after re-starting treatment in the short term. This result suggests that the anti-VEGF treatment for DME has a protective effect in short-term treatment delays.

 Aim: Evaluating the anatomical and functional effects of delay in diabetic macular edema treatment due to the COVID-19 lockdown. Material and Methods: DME cases of which anti-vascular growth factor VEGF treatment was interrupted due to COVID-19 lockdown were included in the study. Age, gender, interval time of the treatment delay, number of injections after retreatment and follow-up period were recorded. Visual acuity VA and central macular thickness CMT of the participants at the last visit before the lockdown V0, the first V1 and the last V2 visit after the lockdown were evaluated. The cases were divided into subgroups based on delay in treatment: 18 weeks or less Group-1 and over 18 weeks Group-2. Results: 89 eyes of 89 patients with average age of 63.1 42-80 were included in the study. The average delay in the treatment during the pandemic period was 21.03 12-48 weeks. The average follow-up period after the initiation of retreatment was 31.2 8-52 weeks, and an average of 2.98 1-8 anti-VEGF treatments were carried out during this period. The mean VA of V0, V1 and V2 visits of the whole group were determined as 0.64, 0.64, and 0.63 LogMAR p0.168, respectively, the mean CMT values were found as 383.06, 434.82, and 373.27 microns p0.001, respectively. The mean VA of V0, V1 and V2 visits were 0.53, 0.50 and 0.52 LogMAR p0.263 in Group 1 and, 0.78, 0.83 and 0.74 LogMAR p0.176 in Group 2, respectively. The mean CMT values of V0, V1 and V2 visits were found as 358.72, 386.59 and 389.70 microns p0.056 in Group 1 and, 409.09, 486.42 and 355.70 p0.001 in Group 2, respectively. Conclusion: In DME cases, as the delay time in anti-VEGF treatment increased, worsening was observed in CMT, while CMT values improved without any worsening in VA after re-starting treatment in the short term. This result suggests that the anti-VEGF treatment for DME has a protective effect in short-term treatment delays.

 Aim: Evaluating the anatomical and functional effects of delay in diabetic macular edema treatment due to the COVID-19 lockdown. Material and Methods: DME cases of which anti-vascular growth factor VEGF treatment was interrupted due to COVID-19 lockdown were included in the study. Age, gender, interval time of the treatment delay, number of injections after retreatment and follow-up period were recorded. Visual acuity VA and central macular thickness CMT of the participants at the last visit before the lockdown V0, the first V1 and the last V2 visit after the lockdown were evaluated. The cases were divided into subgroups based on delay in treatment: 18 weeks or less Group-1 and over 18 weeks Group-2. Results: 89 eyes of 89 patients with average age of 63.1 42-80 were included in the study. The average delay in the treatment during the pandemic period was 21.03 12-48 weeks. The average follow-up period after the initiation of retreatment was 31.2 8-52 weeks, and an average of 2.98 1-8 anti-VEGF treatments were carried out during this period. The mean VA of V0, V1 and V2 visits of the whole group were determined as 0.64, 0.64, and 0.63 LogMAR p0.168, respectively, the mean CMT values were found as 383.06, 434.82, and 373.27 microns p0.001, respectively. The mean VA of V0, V1 and V2 visits were 0.53, 0.50 and 0.52 LogMAR p0.263 in Group 1 and, 0.78, 0.83 and 0.74 LogMAR p0.176 in Group 2, respectively. The mean CMT values of V0, V1 and V2 visits were found as 358.72, 386.59 and 389.70 microns p0.056 in Group 1 and, 409.09, 486.42 and 355.70 p0.001 in Group 2, respectively. Conclusion: In DME cases, as the delay time in anti-VEGF treatment increased, worsening was observed in CMT, while CMT values improved without any worsening in VA after re-starting treatment in the short term. This result suggests that the anti-VEGF treatment for DME has a protective effect in short-term treatment delays.

 Amaç: COVID-19 pandemisi nedeniyle tedaviye verilen aranın diyabetik maküla ödemi DMÖ olgularındaki anatomik ve fonksiyonel etkilerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: COVID-19 nedeniyle anti-vasküler büyüme faktörü VEGF tedavisine ara verilen DMÖ olguları çalışmaya dahil edildi. Olguların yaş, cinsiyet, tedaviye verilen ara süresi ve tekrar tedavi sonrası enjeksiyon sayısı ile takip süresi kaydedildi. Karantina öncesi son vizitleri V0, karantina sonrası ilk V1 ve son vizitlerindeki V2 görme keskinlikleri GK ve optik koherans tomografi ile santral makula kalınlığı SMK değerlendirildi. Olgular tedaviye verilen ara süresine göre 18 hafta ve altı Grup-1 ile 18 hafta üzeri Grup-2 olarak alt gruplara ayrıldı ve analiz edildi. Bulgular: Çalışmaya yaş ortalaması 63,1 yıl 42-80 yıl arası olan 89 olgunun 89 gözü dahil edildi. Pandemi sürecinde tedaviye verilen ara ortalaması 21,03 hafta 12-48 hafta olarak saptandı. Tekrar tedaviye başlanan olguların ortalama takip süresi 31,2 hafta 8 - 52 hafta olup bu süreç içerisinde ortalama 2,98 1-8 anti-VEGF tedavi uygulanmıştı. Tüm grupta V0, V1 ve V2 vizitlerindeki ortalama GK sırasıyla 0,64, 0,64 ve 0,63 LogMAR p0,168, ortalama SMK değerleri sırasıyla 383,06, 434,82 ve 373,27 mikron p0,001 bulunmuştur. Grup 1de V0, V1 ve V2 vizitlerindeki ortalama GK sırasıyla 0,53, 0,50 ve 0,52 LogMAR p0,263; ortalama SMK değerleri sırasıyla 358,72, 386,59 ve 389,70 mikron p0,056 olarak bulunmuştur. Grup 2de V0, V1 ve V2 vizitlerindeki ortalama GK sırasıyla 0,78, 0,83 ve 0,74 LogMAR p0,176; ortalama SMK değerleri sırasıyla 409,09, 486,42 ve 355,70 p0,001 olarak bulunmuştur. Sonuç: DMÖ olgularında Anti-VEGF tedavisinde gecikme süresi arttıkça SMKde kötüleşme izlenirken, kısa dönemde tekrar tedaviye başlanmasıyla GKde bir kötüleşme olmadan SMK değerlerinde düzelme elde edilmiştir. Bu sonuç, olgulara daha önce uygulanan anti- VEGF tedavinin kısa dönemli tedavi gecikmelerinde koruyucu olduğunu düşündürmektedir.

Article Details

Effects of COVID-19 Lockdown on Diabetic Macular Edema Treatment

Authors:

Serdar Bilici | Neriman Selçuk | Tuba Gültekin-erol | Suat Hayri Uğurbaş

Publisher:

Zonguldak Bulent Ecevit University

Main Topics:

Sağlık Kurumları Yönetimi

Journal:

Türkiye Diyabet ve Obezite Dergisi Vol.7 Issue 2, pp.122-127

Document Type:

Article

Publication Date:

8/2023

Document Language:

Turkish

Document ID (Org No.):

2001297818

pISSN:

2587-0335

Anti-vascular growth factor

COVID-19

Diabetic macular edema

Optical coherence tomographyAnti-vaskuler büyüme faktörü

COVID-19

Diyabetik makula ödemi

Optik koherens tomografi

Issues

Article Details

Authors: Serdar Bilici | Neriman Selçuk | Tuba Gültekin-erol | Suat Hayri Uğurbaş

Publisher: Zonguldak Bulent Ecevit University

Main Topics: Sağlık Kurumları Yönetimi

Journal: Türkiye Diyabet ve Obezite Dergisi Vol.7 Issue 2, pp.122-127

Document Type: Article

Publication Date: 8/2023

Document Language: Turkish

Document ID (Org No.): 2001297818

pISSN: 2587-0335

Issues

Authors:

Serdar Bilici | Neriman Selçuk | Tuba Gültekin-erol | Suat Hayri Uğurbaş

Publisher:

Zonguldak Bulent Ecevit University

Main Topics:

Sağlık Kurumları Yönetimi

Journal:

Türkiye Diyabet ve Obezite Dergisi Vol.7 Issue 2, pp.122-127

Document Type:

Article

Publication Date:

8/2023

Document Language:

Turkish

Document ID (Org No.):

2001297818

pISSN:

2587-0335